1. Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
- Author
-
Chung, Young Shin, Kim, Yun-Ji, Lee, Inha, Lee, Jung-Yun, Nam, Eun Ji, Kim, Sunghoon, Kim, Sang Wun, and Kim, Young Tae
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Ovarian Cancer ,Clinical Research ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,6.4 Surgery ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Antineoplastic Combined Chemotherapy Protocols ,Chemotherapy ,Adjuvant ,Disease-Free Survival ,Female ,Humans ,Kaplan-Meier Estimate ,Linear Models ,Middle Aged ,Neoadjuvant Therapy ,Neoplasm Staging ,Ovarian Neoplasms ,Postoperative Period ,Retrospective Studies ,Time Factors ,Treatment Outcome ,General Science & Technology - Abstract
BackgroundThere is currently no consensus regarding the optimal number of chemotherapy cycles to be administered before and after interval debulking surgery (IDS) in patients with advanced ovarian cancer. This study aimed to evaluate the impact of the number of neoadjuvant chemotherapy (NAC) and postoperative adjuvant chemotherapy (POAC) cycles on the survival of patients with advanced ovarian cancer undergoing NAC/IDS/POAC.MethodsWe retrospectively reviewed data from 203 patients who underwent NAC/IDS/POAC at Yonsei Cancer Hospital between 2006 and 2016. All patients underwent taxane plus carboplatin chemotherapy for NAC and POAC. The patient outcomes were analyzed according to the number of NAC, POAC, and total chemotherapy (NAC+POAC) cycles.ResultsPatients who received fewer than 6 cycles of total chemotherapy (n = 8) had poorer progression-free survival (PFS) and overall survival (OS) than those completing at least 6 cycles (p = 0.005 and p
- Published
- 2017